JPS60259187A - プラスミノーゲン活性化因子を増収する方法 - Google Patents
プラスミノーゲン活性化因子を増収する方法Info
- Publication number
- JPS60259187A JPS60259187A JP60081493A JP8149385A JPS60259187A JP S60259187 A JPS60259187 A JP S60259187A JP 60081493 A JP60081493 A JP 60081493A JP 8149385 A JP8149385 A JP 8149385A JP S60259187 A JPS60259187 A JP S60259187A
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- present
- plasminogen activator
- cell line
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000001938 Plasminogen Activators Human genes 0.000 title claims description 60
- 108010001014 Plasminogen Activators Proteins 0.000 title claims description 60
- 229940127126 plasminogen activator Drugs 0.000 title claims description 60
- 238000004519 manufacturing process Methods 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims description 105
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 43
- 239000012894 fetal calf serum Substances 0.000 claims description 35
- 239000001963 growth medium Substances 0.000 claims description 32
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 28
- 239000002609 medium Substances 0.000 claims description 26
- 102000004877 Insulin Human genes 0.000 claims description 14
- 108090001061 Insulin Proteins 0.000 claims description 14
- 230000012010 growth Effects 0.000 claims description 14
- 229940125396 insulin Drugs 0.000 claims description 14
- 102000004338 Transferrin Human genes 0.000 claims description 12
- 108090000901 Transferrin Proteins 0.000 claims description 12
- 229940098773 bovine serum albumin Drugs 0.000 claims description 12
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 12
- 102000013361 fetuin Human genes 0.000 claims description 12
- 108060002885 fetuin Proteins 0.000 claims description 12
- 239000012581 transferrin Substances 0.000 claims description 12
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 11
- 229960003957 dexamethasone Drugs 0.000 claims description 11
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 6
- 210000001072 colon Anatomy 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 102000013566 Plasminogen Human genes 0.000 claims description 3
- 108010051456 Plasminogen Proteins 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 229960003473 androstanolone Drugs 0.000 claims description 2
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 8
- 239000012888 bovine serum Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60186884A | 1984-04-19 | 1984-04-19 | |
| US601868 | 1984-04-19 | ||
| US704593 | 1985-02-22 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2276605A Division JPH03151873A (ja) | 1984-04-19 | 1990-10-17 | プラスミノゲン活性化因子産生細胞系 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60259187A true JPS60259187A (ja) | 1985-12-21 |
| JPH0358270B2 JPH0358270B2 (enrdf_load_stackoverflow) | 1991-09-04 |
Family
ID=24409076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60081493A Granted JPS60259187A (ja) | 1984-04-19 | 1985-04-18 | プラスミノーゲン活性化因子を増収する方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60259187A (enrdf_load_stackoverflow) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5728009A (en) * | 1980-06-11 | 1982-02-15 | Leuven Res & Dev Vzw | Novel plasminogen activator and drug having thrombosis dissolving activity |
| JPS5865219A (ja) * | 1981-07-15 | 1983-04-18 | イエダ・リサ−チ・アンド・デベロツプメント・コンパニ−・リミテツド | プラスミノ−ゲン賦活体の製造法 |
| JPS59134733A (ja) * | 1983-01-24 | 1984-08-02 | Asahi Chem Ind Co Ltd | 生物活性物質の製法 |
-
1985
- 1985-04-18 JP JP60081493A patent/JPS60259187A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5728009A (en) * | 1980-06-11 | 1982-02-15 | Leuven Res & Dev Vzw | Novel plasminogen activator and drug having thrombosis dissolving activity |
| JPS5865219A (ja) * | 1981-07-15 | 1983-04-18 | イエダ・リサ−チ・アンド・デベロツプメント・コンパニ−・リミテツド | プラスミノ−ゲン賦活体の製造法 |
| JPS59134733A (ja) * | 1983-01-24 | 1984-08-02 | Asahi Chem Ind Co Ltd | 生物活性物質の製法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0358270B2 (enrdf_load_stackoverflow) | 1991-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2534020B2 (ja) | 血清不含培地による組織プラスミノ―ゲン活性化物質の製造方法 | |
| Pearistein et al. | Surface proteins and fibrinolytic activity of cultured mammalian cells | |
| Marotti et al. | The production of distinct forms of plasminogen activator by mouse embryonic cells | |
| Mort et al. | A latent thiol proteinase from ascitic fluid of patients with neoplasia | |
| EP0158958B1 (en) | Method and cell line for obtaining plasminogen activators | |
| Kao et al. | Collagenases in human breast carcinoma cell lines | |
| Caspers et al. | Expression of γ-glutamyltranspeptidase in a transformed rat cerebral endothelial cell line | |
| Chou et al. | Cell density‐dependent secretion of plasminogen activator by 3T3 cells | |
| Hisazumi et al. | Fibrinolytic activity of in vitro cultivated human bladder cell lines | |
| US4851346A (en) | Chemically defined growth medium | |
| JPS60259187A (ja) | プラスミノーゲン活性化因子を増収する方法 | |
| HU200792B (en) | Process for producing new fibrinolytic enzymes and pharmaceutical compositions comprising such enzymes as active ingredient | |
| Hoal-Van Helden et al. | Characterization of seven human melanoma cell lines: melanogenesis and secretion of plasminogen activators | |
| CA1267621A (en) | Method and cell line for obtaining plasminogen activators | |
| Christman et al. | Specificity of response in hamster cells induced to produce plasminogen activator by the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate | |
| Vailhe et al. | Description of an in vitro angiogenesis model designed to test antiangiogenic molecules | |
| EP0151996A2 (en) | Process for the Preparation of a double-chain plasminogen activator | |
| Gumińska et al. | Pyruvate kinase inhibited by L-cysteine as a marker of tumorigenic human urothelial cell lines | |
| Poiley et al. | Characterization of normal human embryo cells grown to over 100 population doublings | |
| Urade et al. | Continuous culture of human melanoma cells in protein-free medium: establishment and partial characterization | |
| Acker et al. | Endothelial cell mitogen released from HT29 tumour cells grown in monolayer or multicellular spheroid culture | |
| JP2620299B2 (ja) | 新規プロテアーゼ及び該プロテアーゼ産生細胞株 | |
| JP2879906B2 (ja) | プロコラゲナーゼの製造方法 | |
| Ganea et al. | A serine proteinase inhibitor produced by an HTLV I virus-transformed human T lymphocyte line. | |
| White et al. | Altered biochemical properties of mitochondria in mouse mammary epithelial cells during primary culture |